Align Technology, Inc. (ALGN) fair value analysis
S&P 500 & Nasdaq · Updated 2026-10-19
ALGN price how computed
Forward Fair Value verdict
UndervaluedALGN is trading at more than a 25% discount to estimated fair value.
Based on TickrTrends' weekly Forward Fair Value model.
- Last price
- $142.71
- Sector
- Healthcare
- 12-month range
- $131.91–$197.51
- Market cap
- $10.1B
- From 52-week high
- -27.7%
- Shares outstanding
- 71M
- Rank in Healthcare by discount to fair value
- #4 of 108
Last price is our 2026-10-19 weekly price; the chart runs through 2026-10-16.
Align Technology, Inc. manufactures and sells clear aligner systems and other orthodontic products used to straighten teeth, along with digital scanning and treatment planning software for dental professionals. The company operates globally, serving orthodontists, general dentists, and patients across multiple countries through direct sales and distribution channels.
ALGN currently ranks #4 of 108 Healthcare stocks by discount to fair value. It has screened as Undervalued for 14 consecutive weekly runs.
Fundamentals (4 quarters) how computed
- Market cap
- $10.1B
- P/E (trailing)
- 14x
- Revenue (TTM)
- $4.14B
- Net margin
- 10.0%
- EPS (TTM)
- $10.53
- Gross margin
- 65.1%
- Debt / equity
- 0.03
- Revenue growth (3-yr avg)
- 3.3%
- Shares outstanding
- 71M
Derived indicators how computed
- Quality grade
- B
- Margin trend
- Contracting
- 52-week position
- The bottom quarter of its range
- DCF cross-check
- Overvalued
Technicals how computed
- RSI (14-day)
- 50 · neutral
- 50-day average
- $154.31
- 200-day average
- $169.51
- Moving-average state
- 50-day below 200-day (death cross state); price below both averages
Earnings how computed
- Next earnings report
- 2026-10-28 (post-market)
- Last 8 quarters vs consensus
- 5 beat, 3 missed
- Quarter by quarter
- 2026-06 ▼ miss (-1.4%)
2026-03 ▲ beat (+12.7%)
2025-12 ▲ beat (+10.8%)
2025-09 ▲ beat (+8.3%)
2025-06 ▼ miss (-3.1%)
2025-03 ▲ beat (+7.1%)
2024-12 ▼ miss (-0.4%)
2024-09 ▲ beat (+1.7%)
Analyst consensus how computed
This is not TickrTrends' verdict.
- Analyst ratings
- 10 buy · 5 hold · 1 sell (16 analysts)
- Consensus lean
- Buy-leaning
- Consensus price target
- $194
- Target vs last price
- +35.9%
What our data shows for ALGN
- Our model validated 17 trailing price-to-earnings windows for ALGN, built from quarterly earnings records.
- Shares are trading in the lower third of their 12-month price range of $131.91–$197.51.
- The 14-day relative strength index sits at a neutral 50.
The exact numbers are one step away
- The precise Forward Fair Value dollar figure for ALGN
- Exact discount / premium to today's price
- The normalized historical P/E behind the estimate, and how many quarters support it
- Forward EPS input and fiscal-year basis
- Screeners and rankings across the full S&P 500 and Nasdaq universes
Forward Fair Value applies a conservatively normalized historical price-to-earnings multiple to the consensus earnings estimate for the next full fiscal year; how TickrTrends computes it.
Recent ALGN news
TickrTrends' derived news-sentiment signal for ALGN is currently leaning positive, computed from recent coverage.
- ALGN Maintained by Piper Sandler -- Price Target Lowered to $205 (gurufocus.com, 2026-10-21)
TickrTrends take: Piper Sandler's price target reduction to $205 occurs within a context where TickrTrends currently assesses ALGN as undervalued, suggesting the market may be pricing in more pessimism than fundamental metrics support. For valuation-focused investors monitoring the Healthcare sector, this analyst adjustment provides a checkpoint to evaluate whether the company's underlying business quality justifies the current gap between market pricing and intrinsic value estimates. The maintenance of coverage alongside the target reduction indicates continued analyst engagement with the stock despite near-term headwinds. - Align Technology (ALGN) Wins European Patent Infringement Ruling Against Angelalign (gurufocus.com, 2026-10-18)
TickrTrends take: Align Technology's European patent victory against competitor Angelalign strengthens its intellectual property moat in a key market, which typically supports pricing power and market position for Healthcare sector companies. Since TickrTrends currently assesses ALGN as undervalued, investors monitoring this patent ruling should consider how successful enforcement of proprietary technology might affect the company's competitive advantages and long-term revenue sustainability. Patent wins can reduce competitive pressure and protect market share, factors that valuation models incorporate when reassessing a company's growth trajectory and defensive characteristics. - ALGN Downgraded by Baird -- Price Target Lowered to $162 (gurufocus.com, 2026-10-15)
TickrTrends take: Align Technology's downgrade by Baird to a price target of $162 represents a significant analyst reassessment that investors tracking valuation metrics should monitor closely against TickrTrends' current undervalued designation. The gap between analyst price targets and current market valuation will be a key indicator for whether the undervalued thesis holds or whether the downgrade signals deteriorating fundamental conditions that warrant reassessment. Valuation-focused readers should watch whether this analyst action prompts broader sentiment shifts in the Healthcare sector or if it provides a buying opportunity consistent with the undervalued rating.
More ALGN news
- ALGN Maintains Rating by Leerink Partners -- Price Target Lowered to $215 (gurufocus.com, 2026-10-14)
- Federal Appeals Court Reverses Ruling Against Align Technology (ALGN), Raising Antitrust Concerns (gurufocus.com, 2026-10-05)
- ALGN Downgraded by Evercore ISI Group -- Price Target Lowered to (gurufocus.com, 2026-10-05)
- Align Technology Inc (ALGN) Shares Surge 4.4% -- What GF Score of 85 Tells Investors (gurufocus.com, 2026-09-22)
What people are saying
Follow the ALGN conversation: Stocktwits · Reddit · X
TickrTrends weekly updates
- 2026-10-19 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-12 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-11 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-10 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-06 — No material change this week: the verdict, bands and grades all held steady.
- 2026-09-28 — No material change this week: the verdict, bands and grades all held steady.
- 2026-09-21 — ALGN's relative strength index moved from oversold territory into neutral range this week, suggesting reduced downward momentum in the Healthcare sector stock. With the current valuation verdict showing Undervalued, the shift in RSI zone indicates a potential stabilization in price action from the previous week's more deeply depressed levels.
- 2026-09-17 — No material change this week: the verdict, bands and grades all held steady.
Frequently asked questions
Is ALGN stock undervalued?
Based on TickrTrends' Forward Fair Value model (updated 2026-10-19), ALGN is trading at more than a 25% discount to estimated fair value and screens as undervalued. The exact fair value and discount are available to subscribers.
What is ALGN's TickrTrends verdict?
ALGN's current verdict is Undervalued, refreshed with every weekly Forward Fair Value run.
How does ALGN compare to other Healthcare stocks?
ALGN ranks #4 of 108 Healthcare stocks in TickrTrends' coverage by discount to fair value.
Is ALGN overbought or oversold?
ALGN's 14-day RSI is in neutral territory - neither overbought nor oversold.
When does ALGN report earnings next?
ALGN's next earnings report is scheduled for 2026-10-28 (post-market), per the published earnings calendar.
Does ALGN usually beat earnings estimates?
Over its last 8 reported quarters ALGN beat the consensus estimate 5 times and missed 3 times, by TickrTrends' comparison of reported and estimated EPS.
What do analysts say about ALGN?
Of 16 analysts covering ALGN, 10 rate it a buy, 5 a hold and 1 a sell - buy-leaning, with a consensus price target of $194 (+35.9% versus TickrTrends' last price). This is the analyst consensus, not TickrTrends' Forward Fair Value verdict.
More in Healthcare
Head-to-head comparisons
ALGN vs ADMA · ALGN vs ANIP · ALGN vs ASTH · ALGN vs AZN · ALGN vs BLLN